Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biovaxys Technology Corp
(CSE:
BIOV
)
0.0450
UNCHANGED
Streaming Delayed Price
Updated: 1:19 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
194,998
Open
0.0450
Bid (Size)
0.0400 (240,000)
Ask (Size)
0.0500 (25,000)
Prev. Close
0.0450
Today's Range
0.0450 - 0.0450
52wk Range
0.0100 - 0.1000
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News
April 18, 2023
Via
ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Spey Resources, Melkior Resources and BioVaxys Technology Discussing Their Latest News
March 16, 2023
Via
ACCESSWIRE
Performance
YTD
-10.00%
-10.00%
1 Month
-30.77%
-30.77%
3 Month
-30.77%
-30.77%
6 Month
-30.77%
-30.77%
1 Year
+125.00%
+125.00%
More News
Read More
The Power Play by The Market Herald Releases New Interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology Discussing Their Latest News
December 20, 2022
Via
ACCESSWIRE
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
December 01, 2022
Via
FinancialNewsMedia
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
The Power Play by The Market Herald Releases New Interviews with RDARS, Infinity Stone Ventures, BioVaxys Technology, and Sitka Gold Discussing Their Latest News
October 06, 2022
Via
ACCESSWIRE
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Via
FinancialNewsMedia
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
October 06, 2022
Via
FinancialNewsMedia
The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News
September 28, 2022
Via
ACCESSWIRE
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
May 18, 2022
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
May 18, 2022
Via
FinancialNewsMedia
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
April 25, 2022
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp.
March 30, 2022
From
The Market Herald
Via
AccessWire
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
March 24, 2022
Via
FinancialNewsMedia
Exposures
COVID-19
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
December 07, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
December 07, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
November 09, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
November 09, 2021
Via
FinancialNewsMedia
Topics
Death
Exposures
COVID-19
Death
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
November 09, 2021
Via
FinancialNewsMedia
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
October 20, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
October 20, 2021
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
October 20, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
October 06, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
September 28, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.